Sekisui XenoTech Appoints New COO
News Oct 20, 2017
Sekisui XenoTech has announced the appointment of Dr. Darren Warren, PhD, as the company’s new Chief Operating Officer. Dr. Warren has over 15 years of leadership experience with Contract Research Organizations (CROs) and almost 30 years of leadership experience in the pharmaceutical industry. October 16th marked his first day as COO at Sekisui XenoTech.
Dr. Warren is an accomplished executive with expertise in operations, business, strategy, and science for service sector research organizations. His most recent position prior to Sekisui XenoTech was “Vice President and General Manager” with a west coast CRO, and his extensive industry experience includes Ricerca Biosciences, SNBL USA, Charles River Labs and Bayer Corporation. Dr. Warren obtained his PhD in Pharmacology and Toxicology from the University of California, Davis in 1986.
Dr. Warren specializes in identifying and accelerating strategic and operational measures that strengthen performance with sustained multi-million dollar operational results. Dr. Toshinari Ohara, PhD, CEO of Sekisui XenoTech, added, “Dr. Warren’s demonstrated proficiency at combining expertise with methodical and pragmatic approaches to meet the challenges faced by today’s research industry, along with strong insights into emerging opportunities, trends, and issues, made him the clear choice for this position. Darren is committed to the highest level of quality, professionalism and excellence, which is in perfect alignment with Sekisui XenoTech’s philosophy.”
Upon joining Sekisui XenoTech, Darren noted, “I am excited to become a member of an organization with the distinguished performance history, leadership team strength, depth of scientific expertise, and position of market leadership that Sekisui XenoTech enjoys, and that holds an optimistic outlook toward the future growth while maintaining commitment to excellence in providing a positive customer experience as well as outstanding contract services and products.”
International Conference on Clinical Trials & Pharmacovigilance
Feb 28 - Mar 01, 2019